Abstract
Background While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear.
Methods We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at year two of antiretroviral therapy (ART) could predict the risk of serious non-AIDS events (SNAEs) during the next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, and non-accidental deaths. We used pooled logistic regression with inverse probability weighting to estimate the survival curves and cumulative risk of clinical events.
Results The study included 4625 participants, of whom 4.3% experienced an SNAE during the follow-up period. A CD4/CD8 ratio <0.3 predicted an increased risk of SNAEs during the next five years (OR 1.63, 95%CI 1.03-2.58). The effect was stronger at a CD4/CD8 ratio cut-off of <0.2 (OR 3.09, 95%CI 1.57-6.07). Additionally, low CD4 count at cut-offs of <500 cells/μL predicted an increased risk of clinical events. Among participants with a CD4 count ≥500 cells/μL, a CD8 count ≥1500 cells/μL or a CD4/CD8 ratio <0.4 predicted increased SNAE risk.
Conclusions Our results support the use of the CD4/CD8 ratio and CD8 count as predictors of clinical progression. Patients with CD4/CD8 ratio <0.3 or CD8 count ≥1500/μL, regardless of their CD4 count, may benefit from closer monitoring and targeted preventive interventions.
Summary This study found that a low CD4/CD8 ratio (<0.3) or a CD8 count ≥1500/μL after two years of antiretroviral therapy predicts an increased risk of serious non-AIDS events, regardless of CD4 count. These patients may benefit from closer follow-up.
Competing Interest Statement
J.M.-S. reports personal fees from ViiV Healthcare, Janssen Cilag, Gilead Sciences, and MSD, non-financial support from ViiV Healthcare, Jannsen Cilag, and Gilead Sciences, and research grants from Gilead Sciences, outside the submitted work. S. S.-V. reports personal fees from Gilead Sciences, MSD, Mikrobiomik, and Aptatargets, non-financial support from ViiV Healthcare and Gilead Sciences, and research grants from MSD and Gilead Sciences, outside the submitted work. S.M. reports grants, personal fees and non-financial support from ViiV Healthcare, personal fees, and non-financial support from Janssen, grants, personal fees and non-financial support from MSD, grants, personal fees, and non-financial support from Gilead, outside the submitted work.
Funding Statement
This work was supported by CIBER (Consorcio Centro de Investigacion Biomedica en Red, CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea, NextGenerationEU; by the Spanish AIDS Research Network (RIS) RD16/0025/0001 project as part of the Plan Nacional R + D + I, and cofinanced by Instituto de Salud Carlos III (ISCIII) Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER), ISCIII projects PI18/00154, PI21/00141, and ERDF, "A way to make Europe", ICI20/00058. The funders had no role in the study design, data analysis, or in the interpretation of the results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards of the Carlos III Health Institute, Madrid, Spain, and by the Ethics Committee at the University Hospital Ramon y Cajal (ceic.hrc{at}salud.madrid.org).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵b Co-senior authors
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos